Drug intelligence / Profile preview

brimonidine

Development stage: Approved
Lead developer: Allergan
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

Brimonidine is a highly selective alpha-2 adrenergic receptor agonist and 2-imidazoline derivative used primarily to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is also approved for the topical treatment of persistent facial erythema associated with rosacea. Brimonidine acts by reducing aqueous humor production and increasing uveoscleral outflow in the eye. Its selectivity for alpha-2 over alpha-1 adrenergic receptors minimizes systemic side effects and unwanted ocular effects compared to less selective agents. For rosacea, its vasoconstrictive action on peripheral blood vessels reduces facial redness[3][4][5][6][8].

Brand names: AlphaganAlphagan-PMirvasoLumifyBrymont
Other names: brimonidine tartrate

Targets

ADRA2A (α2A)

Beyond the preview

Go deeper on brimonidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on brimonidine.

Explore the full profile